RxDoctor Payments Data

Ellen Ratay, APRN

Acute Care · Beavercreek, OHNPI 1114260270

Payments from drug & device makers

$3,317in general payments, 2019–2025

Across 158 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$583
  • QOL Medical, LLC$256
  • Sanofi$178
  • Takeda Pharmaceuticals U.S.A., Inc.$139
  • Evoke Pharma, Inc.$138
  • plus $854 from 18 others

What the payments were for

  • Food & beverage$3,317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,317 in reported general payments places this provider in the 90th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$91,619
Medicare patients
381
Services billed
3,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase22$36,796
LinzessLinaclotide28$21,699
Mesalamine ErMesalamine11$4,623
Esomeprazole Magnesium111$3,414
Pantoprazole Sodium258$3,278
Dexlansoprazole DrDexlansoprazole19$2,564
Budesonide EcBudesonide13$2,129
Colestipol Hcl32$2,105
Famotidine219$1,903
Budesonide DrBudesonide25$1,204
Dicyclomine Hcl74$1,098
Sucralfate29$851
Omeprazole133$797
Ondansetron Hcl51$789
Ondansetron OdtOndansetron24$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,169$58,49550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,101 acute care providers in Ohio.

Other acute care in Beavercreek

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →